BMW Marks 50 Years of Iconic Art Car Collection with Global Exhibition Tour
BMW's iconic Art Car collection is celebrating its 50th anniversary in 2025, launching a global exhibition tour highlighting the unique convergence of automotive engineering and contemporary art.
Since its inception in 1975, when American sculptor Alexander Calder turned a BMW 3.0 CSL race car into a vivid, rolling canvas, BMW's Art Car initiative has drawn some of the art world's most influential figures, including Andy Warhol, Roy Lichtenstein, Jeff Koons, and Jenny Holzer. To date, 20 renowned artists have transformed BMW vehicles into dynamic artworks, making the series one of the automotive world's most ambitious and celebrated cultural endeavors.
To mark half a century of collaboration, BMW announced its largest-ever international tour for the Art Car series, featuring special events and exhibitions spanning five continents. The collection represents an extraordinary timeline of art history, encompassing minimalism, pop art, conceptualism, abstraction, and digital expression.
'Our 20 BMW Art Cars have become global icons, narrating stories about society, technology, and performance," said Ilka Horstmeier, BMW Group Board Member for Human Resources and Real Estate. "This anniversary highlights our enduring commitment to fostering innovation and creativity through meaningful artistic partnerships.'
Julie Mehretu's recent work, the BMW M Hybrid V8—the 20th Art Car—will make prominent appearances, including exhibitions at Art Basel in Hong Kong and the Shanghai Auto Show. Beyond the car itself, Mehretu's project includes workshops for young filmmakers and media artists in five African countries, culminating in an exhibition at Zeitz MOCAA in Cape Town in 2026.
Other milestone events include a European kickoff featuring Warhol, Lichtenstein, and Koons at Vienna's Museum of Applied Arts and SPARK Art Fair, followed by appearances at prestigious events such as the Concorso d'Eleganza Villa d'Este in Italy and special museum exhibitions across Europe and Asia.
To commemorate the anniversary, BMW will release a third edition of its comprehensive Art Car catalogue, a new limited-edition scale model of Mehretu's car, and a new fashion collection in partnership with Puma.
The BMW Art Car project, first envisioned by racing driver Hervé Poulain and BMW Motorsport chief Jochen Neerpasch, has evolved into a globally recognized fusion of automotive and contemporary art, continuously inspiring new dialogues between artists and automotive enthusiasts alike.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
an hour ago
- UPI
Boeing machinists who build fighter jets reject contract, plan strike
A large American flag is hoisted behind a Boeing F/A-18 E1 Super Hornet jet before dedication ceremonies at the National Museum of Transportation in Kirkwood, Mo., on August 3, 2024. Machinists at three plants in the St. Louis area the product fight jets rejected a contract. File Photo by Bill Greenblatt/UPI | License Photo July 27 (UPI) -- Several thousand Boeing union workers at three St. Louis-area plants who build fighter jets are planning to go on strike after rejecting a proposed contract Sunday that would pay an average of than $100,000 per year. Members of the International Association of Machinists and Aerospace Workers at Boeing factories in St. Louis and St. Charles in Missouri and Mascoutah in Illinois voted against the new contract that included a 20% wage increase over four years. The contract for District 837 members will expire at 11:59 p.m. CDT at which point there is a seven-day cooling-off period before a strike could start. In all, there are 16,000 employees at the three locations, according to St. Louis Business Journal Research. "IAM Union members delivered a clear message: the proposal from Boeing Defense fell short of addressing the priorities and sacrifices of the skilled IAM Union workforce," the union said in a news release. "Our members are standing together to demand a contract that respects their work and ensures a secure future." Boeing and the union representing the machinists on Thursday reached an agreement on a four-year contract that would boost annual salaries to $102,600 with an 8% increase in the first year and 4% for the other three years. "This contract puts money in members' pockets, protects healthcare access, and ensures our members have a voice in future health decisions all while respecting the skill and dedication IAM workers bring to Boeing's critical defense programs," IAM Union International President Brian Bryant said after the tentative contract. The total increase would be 40% when including other benfits. There was a $5,000 ratification bonus. Boeing said the current average hourly pay of $35 is $6 higher than three years ago. "The IAM Union remains committed to achieving a fair contract that meets the needs of our members," the union said. "The IAM Union looks forward to returning to the bargaining table with Boeing's leadership to deliver meaningful improvements that support the well-being and livelihoods of IAM members and their families." IAM, with approximately 600,000 active and retired workers, is one of North America's largest and most diverse industrial trade unions. They represent workers in aerospace/airlines, defense, shipbuilding, railroads/transit, healthcare and automotive in the United States and Canada. "We're disappointed our employees voted down the richest contract offer we've ever presented to IAM 837 which addressed all their stated priorities," Dan Gillian, Boeing Air Dominance vice President, said in a statement, obtained by KSDK-TV. "We've activated our contingency plan and are focused on preparing for a strike. No talks are scheduled with the union." Last year, Boeing machinists in the Pacific Northwest were in a 54-day strike that shut down airplane production. Ultimately, they agreed to an immediate pay boost of 13% and a total of 44% over four years when compounded. Boeing has more than 170,000 employees worldwide. The vote came two days before Boeing plans to announce its second-quarter earnings.
USA Today
3 hours ago
- USA Today
Trump and EU reach trade deal ahead of looming deadline
The trade deal echoes the arrangement Trump reached with Japan. President Donald Trump announced July 27 the United States had reached a trade deal with the European Union, days ahead of a self-imposed Aug. 1 deadline. Trump met with the European Commission's president, Ursula von der Leyen, during his trip to Scotland over the weekend, where the pair discussed terms and came to an agreement. The deal includes a 15% tariff on most European exports to the United States, similar to agreements struck recently between Trump and other major trading partners, including Japan. The levy is higher than the 10% rate sought by Europeans but a reduction from the 30% Trump threatened to impose earlier in July. The agreement also includes $600 billion in EU investments in the U.S., and the purchase of $750 billion worth of U.S. energy. "I think we both wanted to make a deal,' Trump said. "I think it's going to be great for both.' The 15% tariff will be applied 'across the board,' for items including cars, but steel and aluminum will remain at 50%. "We have a trade deal between the two largest economies in the world, and it's a big deal,' von der Leyen said. 'It's a huge deal. It will bring stability. It will bring predictability.' The president has repeatedly criticized the European Union, saying it was "formed to screw the United States" on trade. The U.S. trade deficit with the EU reached $235 billion in 2024, according to U.S. Census Bureau data. Heading into the weekend meeting, he called the relationship between the EU and the United States "very unfair" and said he thought officials had a "50/50 chance" of striking a deal. After an agreement was announced, von der Leyen said the deal would "rebalance" relations, despite European leaders long claiming there was not an unfair trade balance. German Chancellor Friedrich Merz said the agreement averted a trade conflict that threatened a 27.5% tariff on cars. "This agreement has succeeded in averting a trade conflict that would have hit the export-orientated German economy hard,' Merz said. Italy's Prime Minister Giorgia Meloni called it a 'positive' trade deal. Ireland's Trade Minister Simon Harris said the tariff provides certainty in trade that 'is essential for jobs, growth and investment.' "A deal provides a measure of much needed certainty for Irish, European and American businesses who together represent the most integrated trading relationship in the world,' Harris said. Trump is seeking to reorder the global economy and reduce decades-old U.S. trade deficits. He has so far reeled in agreements with Britain, Japan, Indonesia and Vietnam, although his administration has failed to deliver on a promise of "90 deals in 90 days." The EU deal echoes the deal reached with Japan. Despite the recent deals, Commerce Secretary Howard Lutnick said the administration will continue to pursue aggressive tariffs around the world, including potential duties on critical semiconductors in the near future. Contributing: USA TODAY, Reuters
Yahoo
3 hours ago
- Yahoo
Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore
Collaboration focuses on advancing clinically validated armored CAR technologies into first-in-human trials in Singapore and accelerate translational research from bench-to-bedside SINGAPORE and LEXINGTON, Mass., July 28, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announced the signing of a Memorandum of Understanding (MOU) with the National Cancer Centre Singapore (NCCS). The partnership aims to support collaborative cell therapy research and clinical trials for the treatment of a variety of cancers, including colorectal, pancreatic and ovarian cancers. CAR-T cell therapy is a form of immunotherapy that is currently only approved for use to treat blood cancers, such as certain types of lymphomas and multiple myeloma. As part of the agreement, Elpis will contribute clinically validated technologies for cancer treatment, including multi-mechanism armor, bispecific targeting antibodies, cytokine cocktails, and a rapid mRNA display discovery engine, to drive the development of next-generation cell therapies. These technologies are already being investigated in Elpis' global clinical trials of EPC-002 and EPC-003, with the goal of expanding their translational relevance across multiple tumor types. Plans are also underway for Elpis to establish a laboratory space at NCCS and co-share its equipment to enable more integrated and efficient collaboration. "This partnership reflects our commitment to rapidly advancing innovative immunotherapies from discovery to clinical development through to regulatory review and, hopefully saving patients' lives," said Yan Chen, MD, PhD, Founder and CEO of Elpis Biopharmaceuticals. "By combining Elpis's proprietary technology with NCCS's clinical expertise, we look forward to accelerating the delivery of these potential groundbreaking new cancer therapies to patients in Singapore and beyond." NCCS will contribute its expertise in clinical research and access to clinical trial infrastructure to support the evaluation of novel cell therapy candidates. "The potential of using cell therapies for solid tumors is still being explored, and this collaboration will enable us to evaluate promising new technologies in a clinical context to address current unmet needs and improve patient outcomes," said Professor Lim Soon Thye, CEO of NCCS. "This is a key collaboration with NCCS' precision immunotherapy program. With our respective strengths and the shared goal of transforming clinical care through translational science, we look forward to offering clinical trials and developing novel cell therapies to better meet the needs of patients in Singapore and the region," added Professor Daniel Tan, Head, Division of Clinical Trials and Epidemiological Sciences and Senior Consultant, NCCS. The collaboration will support the development of bispecific armored CAR-T cell therapies for solid tumors, while Elpis's global leading mRNA display technology will support NCCS in the rapid discovery of human antibodies to novel targets and enable novel modalities to cell therapy and beyond. "The MOU represents an expansion of Elpis's living drug strategy and a key step toward enabling broader clinical translation of our cutting-edge cell therapy technologies," said Chee-Yong Lim, Co-Founder, Co-CEO & Chief Strategy Officer, Elpis Biopharmaceuticals. "Together, we are working to make living drugs a reality for patients with cancers that currently lack effective treatment options." About Elpis Biopharmaceuticals Elpis Biopharmaceuticals is a clinical-stage biopharma company pioneering next-generation cell therapies for the treatment of solid tumors. The company is advancing a pipeline of first- and best-in-class bispecific armored CAR-T therapies designed to overcome the challenges of tumor heterogeneity and the immunosuppressive tumor microenvironment. Its proprietary platforms—including a multi-mechanism armor technology, bispecific targeting antibodies, a cytokine cocktail-based cell manufacturing process, and a rapid mRNA display discovery engine—are integrated to deliver safer, more durable, and more effective therapeutic responses. Elpis's lead programs include EPC-003 for glioblastoma and EPC-002 for a broad range of solid tumors. Elpis Biopharmaceuticals is headquartered in Singapore and Boston, MA. For more information, visit Contact Tiberend Strategic Advisors, Inc. Jonathan Nugent (investors) +1-205-566-3026 jnugent@ Eric Reiss (media) ereiss@ View original content: SOURCE Elpis Biopharmaceuticals Sign in to access your portfolio
